HansBiomed Returns to Profit, Debt Ratio Plunges Below 100%

Consolidated revenue 64.8B KRW (+47.1% YoY), operating profit 6.5B (vs 1.0B), net profit 5.6B (vs -0.8B), turnaround to profit
Separate revenue 36.0B (+36.2% YoY), operating loss 0.5B (vs -2.4B improvement), net loss 0.3B (vs -2.7B improvement)
Consolidated debt ratio 99.98% (vs 273.0% at year-end, significant improvement); total equity 74.0B (vs 33.9B, +118%)
All 539,388 treasury shares disposed; 3rd-party allocation rights offering of 700,000 shares (1.86B) completed (1-year lock-up)
Litigation provision of 22.9B fully paid and settled (risk resolved)
Consolidated operating cash flow -18.5B (one-off litigation payment impact); separate -22.1B
Separate trade receivables allowance rate 55.91% (still high, vs 54.26%)
R&D expenses 2.6B (4.01% of revenue, consolidated)
Key products: skin grafts 29,402M (45.4%), bone grafts 16,572M (25.6%), medical devices 16,595M (25.6%)
Raw material purchases up 56.66% YoY, FX risk remains